CNBC’s Angelica Peebles sits down with Lilly’s Head of Oncology, Jake Van Naarden, to discuss what’s next in Lilly’s oncology ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...